Thalidomide to be tested on patients as bone marrow cancer drug

Thalidomide to be tested on patients as bone marrow cancer drug

TOKYO, Japan - Two officials of Fujimoto Pharmaceutical Corp. speak at a press conference in Tokyoon July 20. They said the company will begin testing thalidomide on patients as a bone marrow cancer treatment as early as in August, more than 40 years after the agent, notorious for severe birth defects, was banned in Japan.

  • Product Code
  • ILEA001110137
  • Registered date
  • 2005/7/20 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2005 Kyodo News
  • Media size
  • 1864 × 1228 pixel
  • Resolution
  • dpi
  • Deployment size
  • 505.90(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

      Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
        U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

        U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

        Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
          NEC's new AI-driven drug discovery business

          NEC's new AI-driven drug discovery business

          NEC Corp. Senior Vice President Osamu Fujikawa (R) and Eric Quemeneur, executive vice president in charge of research and development at French biotechnology company Transgene SA, shake hands at a press conference in Tokyo on May 27, 2019. The two companies will jointly develop tailor-made vaccines for new types of cancer using artificial intelligence, with clinical tests to begin this year. (Kyodo) ==Kyodo
            China's 3rd qtr GDP slips below 7% for 1st time since 2009

            China's 3rd qtr GDP slips below 7% for 1st time since 2009

            BEIJING, Oct. 19 Kyodo - Sheng Laiyun, spokesman for China's National Bureau of Statistics, announces at a press conference in Beijing on Oct, 19, 2015, that China's economy in the July-September quarter grew 6.9 percent from a year earlier. The gross domestic product figure of the world's second-largest economy slipped below 7 percent for the first time in more than six years.
              Toshiba again delays earnings report amid accounting scandal

              Toshiba again delays earnings report amid accounting scandal

              TOKYO, Aug. 31 Kyodo - Toshiba Corp. President Masashi Muromachi holds a press conference in Tokyo on Aug. 31, 2015. The electronics maker further delayed the release of its earnings results, saying it had found new accounting irregularities that could add to Japan's worst corporate scandal in years.
                Honda's group net profit down for 1st time in 3 yrs

                Honda's group net profit down for 1st time in 3 yrs

                TOKYO, April 28 Kyodo - Tetsuo Iwamura, executive vice president of Honda Motor Co., announces the company's earnings results for the year ended in March 2015 at a press conference in Tokyo on April 28, 2015. Honda's group net profit fell for the first time in three years, down 8.9 percent from a year earlier to 522.76 billion yen ($4.4 billion), hurt by recall-related costs and sluggish sales in Japan.
                  Avigan could be formally approved as Ebola drug early 2015

                  Avigan could be formally approved as Ebola drug early 2015

                  TOKYO, Japan - Shigetaka Komori, chief executive officer of Fujifilm Holdings Corp., attends a press conference in Tokyo, Japan, on Nov. 11, 2014, announcing that the company expects its Avigan anti-influenza drug to be formally approved early next year for treating people infected with the Ebola virus. (Kyodo)
                    Keidanren head urges Abe to stick with woman policy

                    Keidanren head urges Abe to stick with woman policy

                    TOKYO, Japan - Sadayuki Sakakibara, head of the Japan Business Federation or Keidanren, speaks at a press conference in Kanazawa, central Japan, on Oct. 20, 2014, urging the government of Prime Minister Shinzo Abe to stick with its policy of empowering women in society despite the recent resignation of two female Cabinet ministers.
                      NTT Docomo to set up machine translation startup

                      NTT Docomo to set up machine translation startup

                      TOKYO, Japan - Minoru Eto (C), head of NTT Docomo Inc.'s R&D Strategy Department, and other officials clasp hands at a press meeting in Tokyo on Sept. 29, 2014, held to announce the launch of a machine translation startup in a joint venture with two other firms. Eto is to assume the presidency of the new company.